Study of MNV-201 for low-risk MDS with anemia
Part of Blood & lymphatic clinical trials.
This study tests a new therapy called MNV-201 for people with low-risk myelodysplastic syndromes (MDS) who have anemia and need regular blood transfusions. The goal is to see if this treatment can help reduce or stop the need for transfusions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have low-risk myelodysplastic syndromes (MDS) with a certain risk score (R-IPSS ≤3).
- You have anemia and need regular blood transfusions (at least 2 units every 4 weeks for the past 8 weeks).
- You have already tried all available standard treatments for your MDS, or you cannot take them for medical reasons.
- You are not eligible for a bone marrow transplant from a donor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new medicine called HS-20106 to see if it can improve anemia (low red blood cells) for people with certain types of MDS. If it works, it might reduce the need for blood transfusions.
This study carefully evaluates people with myelodysplastic syndromes (MDS) and closely related blood disorders using detailed medical, blood, and bone marrow testing. The goal is to better understand these conditions and how they progress, which may help guide future care.
This trial tests an investigational drug, TAK-226, for people with lower-risk myelodysplastic syndromes (MDS) who have anemia. The study aims to see if the drug can help improve blood counts and reduce the need for red blood cell transfusions.
This study tests a new drug called elritercept for people with myelodysplastic syndromes (MDS) who have low blood counts and need regular blood transfusions. The drug aims to boost red blood cell production and reduce or eliminate the need for transfusions, which can improve energy and quality of life.
This study tests a new drug, momelotinib, for people with a low-risk form of myelodysplastic syndrome (MDS) who need red blood cell transfusions and have already tried one other treatment (like ESAs or luspatercept). The goal is to see if momelotinib can help reduce transfusion needs.
This trial tests an experimental drug called AND017 for people with a certain type of myelodysplastic syndrome (MDS) that is low-risk and not linked to a chromosome 5 deletion. The goal is to see if AND017 can help improve low red blood cell counts (anemia) and reduce or avoid the need for blood transfusions.
Hear when a new Myelodysplastic Syndromes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.